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Introduction: Tumor-associated macrophages (TAMs) are recruited 
into cancer-induced stroma and produce a specific microenviron-
ment for cancer progression. CD204 (+) TAMs are reportedly 
related to tumor progression and clinical outcome in some tumors. 
The aim of this study was to clarify the correlation between CD204 
(+) TAMs and the clinicopathological features of lung squamous 
cell carcinoma.
Methods: We investigated the relationships between the numbers 
of CD204 (+) TAMs and clinicopathological factors, microvessel 
density, and the numbers of Foxp3 (+) lymphocytes in 208 consecu-
tively resected cases. We also examined the relationships between the 
numbers of CD204 (+) TAMs and the expression levels of cytokines 
involved in the migration and differentiation of CD204 (+) TAMs.
Results: A high number of CD204 (+) TAMs in the stroma was sig-
nificantly correlated with an advanced p-stage, T factor, N factor, 
and the presence of vascular and pleural invasion. A high number of 
CD204 (+) TAMs in the stroma was also a significant prognostic fac-
tor for all p-stages and p-stage I. Moreover, the numbers of CD204 
(+) TAMs were correlated with the microvessel density and the num-
bers of Foxp3 (+) lymphocytes. A high number of CD204 (+) TAMs 
was strongly correlated with the tissue expression level of monocyte 
chemoattractant protein-1. CD204 (+) TAMs were shown to be sig-
nificant independent prognostic factors in a multivariate analysis.
Conclusions: CD204 (+) TAMs were an independent prognostic fac-
tor in lung squamous cell carcinoma. CD204 (+) TAMs, along with 
other tumor-promoting stromal cells such as regulatory T cells and 
endothelial cells, may create tumor-promoting microenvironments.
Key Words: CD204, Tumor associated macrophages, Non–small-
cell lung carcinoma, Squamous cell carcinoma.
(J Thorac Oncol. 2012;7: 1790–1797)
The tumor microenvironment is composed of not only tumor cells, but also stromal cells including macrophages, 
lymphocytes, fibroblasts, and endothelial cells. Stromal 
cells are known to interact with cancer cells and to produce 
a specific microenvironment capable of influencing tumor 
progression.1 In the host immune system in cancer tissue, 
tumor-associated macrophages (TAMs) as well as cancer-
associated fibroblasts are important components of the tumor 
microenvironment, and some kinds of macrophages are 
known to act on tumor progression.2 Recent immunological 
studies have identified two different functions of polarized 
macrophage activation, as exhibited by classically activated 
(M1) and alternatively activated (M2) macrophage 
phenotypes.3,4 These subpopulations of macrophages have 
different receptor expression patterns and different cytokine 
and chemokine productions. M1-polarized macrophages have 
an interleukin (IL)-12high, IL-23high, IL-10low phenotype and 
defend the body against pathogens and tumor cells by inducing 
interferon-gamma and producing tumor necrosis factor α and 
nitric oxide. M1-polarized macrophages reportedly play a role 
in tumor suppression. However, M2-polarized macrophages 
have an IL-12low, IL-23low, IL-10 high phenotype and have high 
expression levels of class A scavenger receptor (CD204) and 
mannose receptor (CD163).5–7 M2-polarized macrophages play 
a role in tumor-supportive functions, such as tumorigenesis, 
angiogenesis, matrix remodeling, and immune-suppression.8 
Recent studies have reported that the number of CD204-
positive TAMs within a primary tumor is related to tumor 
progression and outcome in glioma, ovarian epithelial tumors, 
pancreatic cancer, and lung adenocarcinoma.6,9–11
Although squamous cell carcinoma of the lung is sec-
ond only to adenocarcinoma of the lung, its treatmentt has not 
yet been sufficiently effective. Recently, the development of 
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cancer therapy targeting cancer stromal cells has been pro-
posed.12 In the current study, we examined whether the num-
bers of CD204 (+) TAMs recruited into the cancer tissue are 
related to clinicopathological factors of lung squamous cell 
carcinoma. Furthermore, we examined the matching correla-
tions between CD204 (+) TAMs and other types of cancer stro-
mal cells, including regulatory T cells and endothelial cells.
MATERIALS AND METHODS
Patients
Between January 2000 and December 2006, a total of 
255 patients with lung squamous cell carcinoma underwent 
surgery with curative intent at our hospital. We excluded 47 
cases with poor-quality surgical specimens, and the remaining 
208 cases were included in this study. The median follow-up 
period was 5.7 years.
Histopathology Studies
Surgical specimens were fixed in 10% formalin or 
methanol and embedded in paraffin. Sections that are 4-μm–
thick were stained using the hematoxylin and eosin method. 
Vascular invasion and pleural invasion were evaluated using 
the Verhoeff-van-Gieson method. The histologic diagnoses 
were based on the third revised World Health Organization 
histologic classification. Disease stages were based on the 7th 
edition of TNM classification.
Evaluation of Clinicopathological Factors
The clinical characteristics were retrieved from the 
available clinical records. The following clinicopathological 
factors were investigated retrospectively to assess their impact 
on survival: age, sex, smoking history, pathologic stage, 
pathologic T status, pathologic nodal involvement, lymphatic 
permeation, vascular invasion, and pleural invasion.
Antibodies and Immunohistochemistry
The slides were deparaffinized with xylene, rehydrated, 
and antigen-retrieved in a microwave oven for 20 minutes. 
After the inhibition of endogenous peroxidase activity, indi-
vidual slides were then incubated overnight at 4°C with 
mouse antihuman CD204 antibody (Scavenger Receptor class 
A-E5; Transgenic, Japan) at a final dilution of 1:400, mouse 
antihuman CD34 antibody (QBEND/10; Acris Antibodies, 
Herford, Germany) at a final dilution of 1:400, and mouse 
monoclonal antihuman Foxp3 antibody (236A/E7; Abcam, 
Japan) at a final dilution of 1:150. The slides were then incu-
bated with EnVision (Dako, Denmark), and the color reaction 
was developed in 2% 3, 3-diaminobenzidine in 50 mM Tris-
buffer (pH7.6) containing 0.3% hydrogen peroxidase. Finally, 
the sections were counterstained with Meyer hematoxylin.
Evaluation of Immunohistochemistry
Two pathologists (S.H. and G.I.) selected a hot spot 
within a section and counted the CD204 (+) TAMs in the 
cancer stroma and nest in five high-power microscopic fields 
(×400; 0.0625 mm2). The average counts were recorded and 
cases were divided into two groups with low and high num-
bers of CD204 (+) TAMs according to the median value. The 
absolute number of Foxp3-positive lymphocytes in the stroma, 
was counted in five randomly selected high-power micro-
scopic fields (×400; 0.0625 mm2), and the average counts were 
recorded. As for the microvessel density (MVD), the five most 
vascular areas (hot spots) in the invasive foci within a section 
were selected, and vessels labeled with anti-CD34 monoclonal 
antibody were counted in five high-power microscopic fields 
(×400; 0.0625 mm2). The average counts were recorded as the 
MVD. In these studies, we selected areas in the central area 
within a cancer tissue, and necrotic areas were excluded.
Tissue Samples, RNA Extraction, Reverse  
Transcription, and Real-Time Polymerase  
Chain Reaction
Total RNA was extracted from 13 lung squamous 
cell carcinoma cases.. Samples of both cancer tissue and 
noncancerous tissue were collected and immediately 
homogenized in QIAzol Lysis reagent (QIAGEN, CA) 
with Tissue Lyser II (QIAGEN) and stored at −80°C until 
use. The total RNA was isolated from the tissues using a 
QIAshredderTM (250) (QIAGEN) and an RNeasy Mini 
Kit (250) (QIAGEN) according to the manufacturer’s 
instructions. The RNA was reverse transcribed to synthesize 
cDNA using a primerscript RT reagent kit (Takara 
Biochemicals, Osaka, Japan). To quantitatively compare the 
mRNA levels of each cytokine, we performed a real-time 
polymerase chain reaction using SYBR Premix Ex TaqII 
(Takara) with the Smart Cycler II (Takara). The sense and 
antisense primers used for quantitative amplification of the 
cytokine mRNAs and for amplification of glyceraldehyde-
3-phosphate dehydrogenase as an internal control are 
shown in (Supplemental Table 1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A347). The amount of 
template cDNA was expressed by the threshold cycles (G), 
determined from the amplification curve (exponential curve), 
and the threshold level for the detection of the polymerase 
chain reaction product. The expression level of each gene 
was reported as the ratio of its expression to the level of 
glyceraldehyde-3-phosphate dehydrogenase gene expression 
in the same sample. The ratio between the level of cytokine 
expression in the cancer tissue to the level of expression in 
the noncancerous tissue was calculated for each case. The 
median number of CD204 (+) TAMs was used to divide the 
cases into high and low CD204 (+) TAM groups.
Statistical Analysis
The distributions of CD204 (+) TAMs in the stroma and 
MVD and Foxp3-positive lymphocytes were tested for cor-
relations by calculating the Spearman rank correlation coef-
ficients. Overall survival (OS) was measured from the date of 
surgery until the date of death from any cause or to the date 
on which the patient was last known to be alive. Recurrence-
free survival (RFS) was measured from the date of surgery 
until the date of recurrence or until the date the patient was 
last known to be disease free. Survival curves were estimated 
using the Kaplan–Meier method, and differences in survival 
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were compared using the log-rank test. A p value less than 
0.05 was considered significant. Statistical analysis software 
(SPSS, version II) was used to perform the analyses.
RESULTS
Correlations between the numbers of CD204 (+) TAMs 
in the cancer stroma and nest and clinicopathological factors.
A representative case of immunohistochemical staining 
results for CD204 is shown in Fig. 1. All the patients were clas-
sified into two groups according to the median values: 30 for 
the stroma, and nine for the nest. A high CD204 (+) TAM count 
in the stroma was significantly correlated with the pathologic 
stage, pathologic T status, pathologic nodal involvement, and 
vascular and pleural invasion (Table 1). However, lymphatic 
permeation was significantly less frequent in the group with a 
high CD204 (+) TAM count in the nest, compared with those 
with a low CD204 (+) TAM count in the nest (Supplemental 
Table 2, Supplemental Digital Content 2, http://links.lww.
com/JTO/A348).
Evaluation of CD204 (+) TAMs in Stroma 
and Nest as Prognostic Factors
The OS and RFS were significantly shorter in the group 
with a high CD204 (+) TAM count in the stroma compared 
with the group with a low CD204 (+) TAM count in the 
stroma, for all stages (p = 0.0005 and p = 0.0002, respec-
tively) (Fig. 2A). In the p-stage I patients, the OS and RFS 
were also significantly shorter in the group with a high CD204 
(+) TAM count in the stroma, compared with the group with 
a low CD204 (+) TAM count in the stroma (p = 0.0154 and 
p = 0.0071) (Fig. 2B). A high CD204 (+) TAM count in the 
stroma was marginally related to the OS and RFS among the 
p-stage II patients (Fig. 2C), but no significant relation with 
prognosis was seen among the p-stage III patients (Fig. 2D). 
In contrast, no relationship was seen between a high CD204 
(+) TAM count in the nest and the prognosis (data not shown).
Correlations among the numbers of CD204 (+) TAMs in 
the stroma, Foxp3-positive lymphocytes, and the microvessel 
density Recent studies showed that CD204 (+) TAMs 
contribute to the development of neovascularization and 
immunesuppression. We examined the numbers of Foxp3 (+) 
lymphocytes (regulatory T cells) and the MVD in all the cases 
(Fig. 3A–D). The numbers of CD204 (+) TAMs in the stroma 
were strongly correlated with the MVD (p < 0.001; r
s
 = 0.471) 
and were moderately correlated with the numbers of Foxp3-
positive lymphocytes (p = 0.034; r
s
 = 0.147) (Fig. 3E and F).
Correlations between the numbers of CD204 (+) TAMs 
in the stroma and cytokine expression in the cancer tissues. 
We examined the expressions of factors involved in the 
recruitment of TAMs, regulatory T cells, and endothelial cells. 
The correlations between MVD monocyte chemoattractant 
protein-1 (MCP-1), IL-10, transforming growth factor β, and 
vascular endothelial growth factor (VEGF) expression and the 
numbers of CD204 (+) TAMs in the tumor tissue specimens 
(n = 13) were analyzed. The ratios of MCP-1 expression in 
the cancer tissues to their levels of expression in noncancer-
ous tissues were significantly higher in the CD204 high group 
(p = 0.032) (Fig. 4A). The ratios of IL-10 and transforming 
growth factor β expressions in the cancer tissues to their 
levels of expression in noncancerous tissue were marginal 
higher in the CD204 high group (p = 0.063 and p = 0.086, 
FIGURE 1. A, Immunohistochemical 
staining of squamous cell carcinoma 
with antihuman CD204 antibody 
for tumor-associated macrophages 
in the stroma and nest. Cases with 
a high number of CD204 (+) TAMs 
in the stroma, and B, a low number 
of CD204 (+) TAMs in the stroma. 
C, Cases with a high number of 
CD204 (+) TAMs in the nest, and D, 
a low number of CD204 (+) TAMs 
in the nest. TAMs, tumor-associated 
macrophages.
1793Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 12, December 2012 CD204-Positive Macrophages are Important Prognostic Predictors
respectively) (Fig. 4B, C). The difference in the expression of 
VEGF between the two groups was not significant (Fig. 4D).
Univariate and Multivariate Analyses of 
Factors Associated with Prognosis
A univariate analysis identified four significant risk fac-
tors for OS: CD204 (+) TAMs in the stroma, p-T status, ves-
sel invasion, and pleural invasion (Table 2). In a multivariate 
analysis, the presence of CD204 (+) TAMs and the p-T status 
were shown to be statistically significant independent predic-
tors of the OS (Table 3).
DISCUSSION
In this study, we first showed that the numbers of CD204 
(+) TAMs in the tumor stroma, but not in the tumor nest, were 
correlated with several conventional prognostic factors in 
squamous cell carcinoma of the lung. Furthermore, we showed 
that the cases with higher numbers of CD204 (+) TAMs in the 
stroma had a poor clinical outcome, particularly in the early 
stages. These results were consisted with previous reports in 
other types of malignancies, such as glioma, ovarian epithelial 
tumors, pancreatic cancer, and lung adenocarcinoma.6,9–11 
Moreover, the numbers of CD204 (+) TAMs were related 
to the numbers of Foxp3 (+) lymphocytes and the MVD. 
These data suggested that in squamous cell carcinoma tissue, 
CD204 (+) TAMs, along with other tumor-promoting stromal 
cells such as regulatory T cells and endothelial cells, create a 
specific microenvironment that supports tumor progression.
TAMs are known to induce the proliferation, sur-
vival, and invasion of tumor cells by producing wide range 
FIGURE 2.  Kaplan–Meier analysis stratified according to a 
high or low number of CD204 (+) TAMs in the stroma. The 
Kaplan–Meier analysis for overall survival and recurrence-
free survival according to the numbers of CD204 (+) TAMs 
in the stroma are shown for all stages A, for p-stage I, B, for 
p-stage II, C, and for p-stage III, D,. TAMs, tumor-associated 
macrophages.
TABLE 1.  Relationship between CD204 (+) Tumor-
Associated Macrophages in Stroma and Clinical Features
Variables
CD204
paLow (n = 93) High (n = 115)
Sex
Male 85 103
Female 8 12 0.6556
Age (yr)
<70 49 63
70≤ 44 52 0.7632
Smoking history
Never smoker 3 10
Smoker 90 105 0.1052
Surgical procedures
Lobectomy + segmentectomy 82 94
Pneumonectomy 11 21 0.2475
Pathological stage
Stage I 56 48
Stage II–IIIA 37 67 0.0081b
T states
T1 34 24
T2–4 59 91 0.0121b
Lymph node metastasis
N(−) 65 60
N(+) 28 55 0.0095b
Vascular invasion
V(−) 37 28
V(+) 56 87 0.0169b
Lymphatic permeation
 Ly(−) 71 87
Ly(+) 22 28 0.9076
Pleural invasion
P(−) 66 68
P(+) 27 47 0.018b
aPearson 2 test.
bp <0.05.
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of factors, such as matrix metalloproteinases (MMP).1,13–16 
Hagemann et al.17 reported that TAMs change to M2 pheno-
type macrophages, CD204 (+) TAMs, after cocultivation with 
ovarian cancer cells. CD204 (+) TAMs showed a significant 
up-regulation of mRNA for the genes MMP−1, −2, −7, −9, 
and −14. Another article reported that the co-cultivation of 
breast cancer cells with macrophages led to the enhanced 
invasiveness of the cancer cells as a result of tumor necrosis 
factor α-dependent MMP-9 secretion from the TAMs.18 These 
observations may explain the enhanced vascular and pleural 
invasion of squamous cell carcinoma cells in the high CD204 
(+) TAMs groups in the current study.
We found that the numbers of CD204 (+) TAMs were 
strongly correlated with the MVD. Kawahara et al.19 showed 
similar results that M2 macrophages were correlated with the 
MVD in gastric cancer. Given the previous report that CD204 
(+) TAMs secrete proangiogenic factors, including VEGF,17 
the positive relation observed between CD204 (+) TAMs and 
the MVD in the present study is understandable. However, 
the numbers of CD204 (+) TAMs were not associated with 
the expression of VEGF in the tumor tissue. This discrepancy 
might be caused by the fact that angiogenesis also depends on 
angiogenic factors other than VEGF.
The number of CD204 (+) TAMs in the stroma was mar-
ginally correlated with the number of Foxp3 (+) lymphocytes, 
which was partly consistent with the results for intrahepatic 
cholangiocarcinoma.20 Foxp3 (+) T cells down-regulate the 
immune response by attenuating the host’s antitumor T cells, 
potentially permitting unrestricted growth, subsequent metas-
tasis, and recurrence.21,22 Taking these into consideration, 
CD204 (+) TAMs may not only enhance tumor cell invasive-
ness directly, but may also create a more tumor-promoting 
microenvironment by recruiting endothelial cells and regula-
tory T cells.
FIGURE 3.  Immunohistochemical 
staining of squamous cell carcinoma 
tissue with antihuman Foxp3 anti-
body and antihuman CD34 antibody. 
A, Cases with a high number of 
Foxp3 positive lymphocytes, and B, 
a low number of Foxp3 positive lym-
phocytes. C, Cases with a high MVD, 
and D, a low MVD. E, Correlations 
between the numbers of CD204 (+) 
TAMs in the stroma and the MVD, 
F, the number of Foxp3 (+) lympho-
cytes. TAMs, tumor-associated mac-
rophages; MVD, microvessel density. 
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FIGURE 4.  Relative mRNA expression in 
CD204-low and CD204-high cases. The 
levels of mRNA expression shown are the 
ratios of expression in cancer tissues relative 
to the expression in noncancerous tissues, 
as determined using a quantitative real-time 
polymerase chain reaction. MCP-1, monocyte 
chemoattractant protein-1; TGF β, transform-
ing growth factor β; VEGF, vascular endothe-
lial growth factor; IL-10, interleukins-10.
TABLE 2.  Univariate Analysis for Overall Survival (N =208)
Variables Category All Cases 5-Year Survival (%) pa
Age
Median, yrs (range) 69 (46–88) 0.1436
<70 112 66
≥70 96 58
Sex Female 20 48 0.3689
Male 188 63
Smoking Never 13 35 0.1894
Ever 195 64
Surgical procedures Lobectomy segmentectomy 176 63 0.2908
Pneumonectomy 32 56
T factor ≤T1 58 84 0.0006b
>T1 150 54
N factor pN0 125 66 0.1891
pN1/pN2 83 56
Lymphatic permeation Absent 158 61 0.4973
Present 50 67
Vascular invasion Absent 65 73 0.0381b
Present 143 57
Pleural invasion Absent 134 70 0.0013b
Present 74 47
CD204 (+) TAMs in stroma Low 93 75 0.0005b
High 115 52
CD204 (+) TAMs in nest Low 91 63 0.5894
High 117 61
aLog-rank test.
bp 0.05.
TAMs, tumor-associated macrophages.
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In the present study, we showed that the tissue expres-
sion of MCP-1 was significantly correlated with the numbers 
of CD204 (+) TAMs. MCP-1 has been reported as a key cyto-
kine that induces the migration, accumulation, and differentia-
tion of the M2 phenotype and contributes to the recruitment of 
CD204 (+) TAMs into the tumor tissue.11,23 Moreover, MCP-1 
can act directly on endothelial cells to promote angiogen-
esis.24 Although no significant association was seen between 
the number of CD204 (+) TAMs and the VEGF mRNA level, 
MCP-1 might contribute to an increase in the MVD.
In this study, there 10 patients received postoperative 
adjuvant chemotherapy and 21 patients received chemother-
apy after recurrence. However, there are no differences in the 
prognosis with or without postoperative adjuvant chemother-
apy (RFS; p = 0.2329, OS; p = 0.2548) and chemotherapy after 
recurrence (OS; p = 0.1318). Among 198 patients who did not 
receive adjuvant chemotherapy, a high number of CD204 (+) 
TAMs in the stroma was also a significant prognostic factor 
for all p-stages and p-stage I (All p-stages: RFS p = 0.0002, 
OS p = 0.0012, p-stageI: RFS p = 0.0169, OS p = 0.0369). 
Therefore CD204-positive TAM was a strongly independent 
prognostic factor, even subtracting the effect of treatment.
In a recent report, the actions of bisphosphonates on 
macrophages not only impaired TAMs recruitment, but also 
inhibited the release of proangiogenic factors capable of 
affecting TAMs by reversing their polarization from the M2 
to the M1 phenotype.25 Moreover, the depletion of TAMs 
by clodrolip, which consists of a liposome encapsulating 
clodronate or zoledronic acid in combination with sorafenib, 
significantly inhibited tumor progression in hepatocellular 
carcinoma in vitro.26 Our current results suggest that the 
targeting of CD204 (+) TAMs may be useful as a supplemental 
therapy for conventional cancer-treatment regimens for lung 
squamous cell carcinoma.
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